Clinical studies recruiting near Farmington

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · University of Connecticut Health Center ( Site 0128) · Merck Sharp & Dohme LLC · NCT06393374 MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Wi
Phase 2 · Weisberg Cancer Treatment Center · National Cancer Institute (NCI) · NCT05564390 Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small C
Phase 3 · Michigan Healthcare Professionals Farmington · NRG Oncology · NCT05624996 A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carbop
Phase 3 · Profound Research, LLC · Hoffmann-La Roche · NCT06793215 Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated C
Phase 3 · Parkland Health Center - Farmington · Alliance for Clinical Trials in Oncology · NCT07321652 Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer
NA · Parkland Health Center - Farmington · Alliance for Clinical Trials in Oncology · NCT07091617 Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Phase 3 · TG Investigational Site · TG Therapeutics, Inc. · NCT05877963 A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone
Phase 3 · Local Institution - 0380 · Celgene · NCT05519085 Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
Phase 3 · Farmington Health Center · NRG Oncology · NCT05946213 Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Phase 2/Phase 3 · Parkland Health Center - Farmington · NRG Oncology · NCT05174169 Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Canc
Phase 3 · Parkland Health Center - Farmington · Alliance for Clinical Trials in Oncology · NCT06632327 Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder
Phase 2 · Clinical Site · Intra-Cellular Therapies, Inc. · NCT06480383 Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)
Phase N/A · Connecticut Children's Medical Center · Novartis Pharmaceuticals · NCT04174157 A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel
Phase 3 · San Juan Oncology Associates /ID# 244387 · AbbVie · NCT04928846 ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathol
Phase 3 · Parkland Health Center - Farmington · Alliance for Clinical Trials in Oncology · NCT06876714 A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lu
Phase 2 · University of Connecticut Health Center · Johnson & Johnson Enterprise Innovation Inc. · NCT06667908 Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SL
Phase 3 · Parkland Health Center - Farmington · National Cancer Institute (NCI) · NCT04269902 Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
Phase 2 · Clinical Site · Intra-Cellular Therapies, Inc. · NCT06701903 An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Phase 3 · Research Site · AstraZeneca · NCT05952557 A Study to Continue the Administration of Deucravacitinib in Participants With Systemic Lupus Erythematosus (SLE) or Dis
Phase 4 · Local Institution - 0001 · Bristol-Myers Squibb · NCT06875960 Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects
Phase N/A · Parkland Health Center - Farmington · Alliance for Clinical Trials in Oncology · NCT04242095 Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Phase 2 · Farmington Health Centre · Canadian Cancer Trials Group · NCT05640999 Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carci
Phase 3 · Weisberg Cancer Treatment Center · National Cancer Institute (NCI) · NCT05256225 Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associate
Phase 3 · University of Connecticut Health Center · Karuna Therapeutics, Inc., a Bristol Myers Squibb company · NCT05980949 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Phase 3 · Clinical Trial Site · Olema Pharmaceuticals, Inc. · NCT06016738 A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With
Phase 3 · University of Connecticut Health Center · Janssen Research & Development, LLC · NCT07258511 Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials
NA · Parkland Health Center - Farmington · Eastern Cooperative Oncology Group · NCT05108298 Total Shoulder Arthroplasty Multi-Center Registry
Phase N/A · University of Connecticut Health Center · Arthrex, Inc. · NCT03511586 Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectab
Phase 2 · Corewell Health Farmington Hills Hospital · NRG Oncology · NCT05327686 Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Phase 3 · Parkland Health Center - Farmington · ECOG-ACRIN Cancer Research Group · NCT04566328

Look up another city

Look up another condition